Amendment and Response to Non-Final Office Action

Page 2 of 16

AMENDMENTS

Please amend the claim as follows

1-42. (canceled)

- 43. (currently amended) A method for obtaining an siRNA molecule for a target gene, wherein said siRNA molecule comprises an antisense sequence that is 19 30 nucleotide bases in length and a sense sequence region that is 19 30 nucleotide bases in length and the sense region comprises a sense sequence that is 19 bases in length and said antisense sequence and said sense sequence form a duplex region of 19 30 base pairs, said method comprising the steps:
 - (a) selecting a target gene;
 - (b) identifying a set of candidate siRNA sequences wherein each candidate siRNA comprises a sense sequence wherein the antisense sequence of each ofsaid candidate siRNA sequences is at least 79% complementary to a region of the target gene;
 - (c) applying to each of said candidate siRNA sequences a computer algorithm, wherein said computer algorithm comprises a set of one or more criteria selected from the group consisting of a presence of A at position 19 of the sense sequence, a presence of A at position 3 of the sense sequence, a presence of U at position 10 of the sense sequence, a presence of A at position 14 of the sense sequence, an absence of C at position 19 of the sense sequence, an absence of G at position 19 of the sense sequence, an absence of G at position 11 of the sense sequence, an absence of G at position 10 of the sense sequence, and an absence of A at position 11 of the sense sequence, wherein said sense sequence occupies positions 1-19 of the sense region and wherein when said candidate siRNA sequence is 20-30 bases in length, bases that are within the sense region that are not within said sense sequence occupy positions 1 to 11 of the sense region and positions 1 to 11 of the sense region are immediately 5' of the 5' end of the sense sequence; appresence of U at position 1 of the antisense sequence or a presence of A at a

Amendment and Response to Non-Final Office Action

Page 3 of 16

position of the sense sequence that is complementary to position 1 of the antisense sequence, a presence of U at position 17 of the antisense sequence or a presence of A at a position of the sense sequence that is complementary to position 17 of the antisense sequence, a presence of A at position 10 of the antisense sequence or a presence of U at a position of the sense sequence that is complementary to position 10 of the antisense sequence, a presence of U atposition 6 of the antisense sequence or a presence of A at a position of the sense sequence that is complementary to position 6 of the antisense sequence, an absence of G at position 1 of the antisense sequence or an absence of C at a position of the sense sequence that is complementary to position 1 of the antisense sequence, an absence of C at position 7 of the antisense sequence or an absence of G at a position of the sense sequence that is complementary toposition 7 of the antisense sequence, an absence of A at position 15 of the antisense sequence or an absence of U at a position of the sense sequence thatis complementary to position 15 of the antisense sequence and an absence of U at position 9 of the antisense sequence or an absence of A at a position of the sense sequence that is complementary to position 9 of the antisensesequence, wherein said positions are defined in reference to the 5' end of the antisense sequence within the duplex region:

- (d) after step (c) selecting a candidate siRNA sequence from the set of candidate siRNA sequences of step (b) as an siRNA sequence for the target gene, wherein said candidate siRNA sequence satisfies said set of one or more criteria; and
- (e) after step (d) synthesizing an siRNA molecule for said target gene, wherein said siRNA molecule for said target gene comprises said siRNA sequence for the target gene, whereby said siRNA molecule for said target gene is obtained.
- 44. (currently amended) The method according to claim 43, wherein the set of one or more criteria includes the presence of U at position 1 of the antisense sequence or the presence of A at a position 10 of the sense sequence that is complementary toposition 1 of the antisense sequence.

Amendment and Response to Non-Final Office Action

Page 4 of 16

45. (currently amended) The method according to claim 43, wherein the set of one or more criteria includes the presence of U at position 17 of the antisense sequence or the presence of A at a position 3 of the sense sequence that is complementary to position 17 of the antisense sequence.

- 46. (currently amended) The method according to claim 43, wherein the set of one or more criteria includes the presence of A at position 10 of the antisense-sequence or the presence of U at a position of the sense-sequence that is complementary to position 10 of the antisense sense sequence.
- 47. (currently amended) The method according to claim 43, wherein the set of one or more criteria includes the presence of U at position 6 of the antisense sequence or the presence of A at a position 14 of the sense sequence that is complementary to position 6 of the antisense sequence.
- 48. (currently amended) The method according to claim 43, wherein the set of one or more criteria includes the absence of G at position 1 of the antisense sequence or the absence of C at a position 19 of the sense sequence that is complementary to position 1 of the antisense sequence.
- 49. (currently amended) The method according to claim 43, wherein the set of one or more criteria includes the absence of C at position 7 of the antisense sequence or the absence of G at a position 13 of the sense sequence that is complementary to position 7 of the antisense sequence.
- 50. (currently amended) The method according to claim 43, wherein the set of one or more criteria includes the absence of A at position 15 of the antisense sequence or the absence of U at a position 5 of the sense sequence that is complementary to position 15 of the antisense sequence.

Amendment and Response to Non-Final Office Action

Page 5 of 16

- 51. (currently amended) The method according to claim 43, wherein the set of one or more criteria includes the absence of U at position 9 of the antisense sequence or the absence of A at a position 11 of the sense sequence that is complementary to position 9 of the antisense sequence.
- 52. (currently amended) The method according to claim 43 further comprising applying one or more additional criteria selected from the group consisting of: a GC content between about 30% and 52%, and at least 2 A or U bases at positions 11-19 1-5 of the antisense sequence or at least 2 A or U bases at positions of the sense sequence that are complementary to positions 1-5 of the antisense sequence and wherein said candidate siRNA that is selected satisfies said one or more additional criteria.
- 53. (currently amended) The method according to claim 43, wherein said candidate siRNA sequence that is selected as said siRNA sequence for the target gene satisfies at least two criteria selected from the group consisting of: the presence of U atposition 1 of the antisense sequence or the presence of A at a position 19 of the sense sequence that is complementary to position 1 of the antisense sequence, the presenceof U at position 17 of the antisense sequence or the presence of A at a position 3 of the sense sequence that is complementary to position 17 of the antisense sequence, the presence of A at position 10 of the antisense sequence or the presence of U at a position 10 of the sense sequence that is complementary to position 10 of the antisense sequence, the presence of U at position 6 of the antisense sequence or the presence of A at a position 14 of the sense sequence that is complementary toposition 6 of the antisense sequence, the absence of G at position 1 of the antisense sequence or the absence of C at a position 19 of the sense sequence that is complementary to position 1 of the antisense sequence, the absence of C at position 7of the antisense sequence or the absence of G at a position 13 of the sense sequence that is complementary to position 7 of the antisense sequence, the absence of A atposition 15 of the antisense sequence or the absence of U at a position 5 of the sense sequence that is complementary to position 15 of the antisense sequence, and the absence of U at position 9 of the antisense sequence or and the absence of A at a

Amendment and Response to Non-Final Office Action

Page 6 of 16

position $\underline{\Pi}$ of the sense sequence that is complementary to position 9 of the antisense sequence.

- 54. (currently amended) The method according to claim 43, wherein said candidate siRNA sequence that is selected as said siRNA sequence for the target gene satisfies at least three criteria selected from the group consisting of: the presence of U at position 1 of the antisense sequence or the presence of A at a position 19 of the sense sequence that is complementary to position 1 of the antisense sequence, the presenceof U at position 17 of the antisense sequence or the presence of A at a position 3 of the sense sequence that is complementary to position 17 of the antisense sequence. the presence of A at position 10 of the antisense sequence or the presence of U at a position 10 of the sense sequence that is complementary to position 10 of the antisense sequence, the presence of U at position 6 of the antisense sequence or the presence of A at a position 14 of the sense sequence that is complementary toposition 6 of the antisense sequence, the absence of G at position 1 of the antisensesequence or the absence of C at a position 19 of the sense sequence that iscomplementary to position 1 of the antisense sequence, the absence of C at position 7 of the antisense sequence or the absence of G at a position 13 of the sense sequence that is complementary to position 7 of the antisense sequence, the absence of A atposition 15 of the antisense sequence or the absence of U at a position 5 of the sense sequence that is complementary to position 15 of the antisense sequence, and theabsence of U at position 9 of the antisense sequence or the absence of A at a position 11 of the sense sequence that is complementary to position 9 of the antisensesequence.
- 55. (canceled)
- 56. (canceled)
- 57. (currently amended) The method according to claim 43, wherein in (c) said method comprises applying the following criteria to each of said candidate siRNA sequences,

Amendment and Response to Non-Final Office Action

Page 7 of 16

the presence of U at position 1 of the antisense sequence or the presence of A at a position 19 of the sense sequence that is complementary to position 1 of the antisensesequence, the presence of U at position 17 of the antisense sequence or the presence of A at a position 3 of the sense sequence that is complementary to position 17 of the antisense sequence, the absence of G at position 1 of the antisense sequence or the absence of C at a position 19 of the sense sequence that is complementary to position 1 of the antisense sequence, the absence of C at position 7 of the antisense sequence or the absence of G at a position 13 of the sense sequence that is complementary toposition 7 of the antisense sequence, and further comprises applying each of the following additional criteria to each of the candidate siRNA sequences; a GC content between about 30% and 52%, and at least 2 A or U bases at positions 1 5 of the antisense sequence or at least 2 A or U bases at positions 15-19 of the sense sequence that are complementary to positions 1.5 of the antisense sequence, and in (d) said siRNA sequence that is selected for said target gene satisfies the criteria of thepresence of U at position 1 of the antisense sequence or the presence of A at a position 19 of the sense sequence that is complementary to position 1 of the antisensesequence, the presence of U at position 17 of the antisense sequence or the presence of A at a position 3 of the sense sequence that is complementary to position 17 of the antisense sequence, the absence of G at position 1 of the antisense sequence or the absence of C at a position 19 of the sense sequence that is complementary to position 1 of the antisense sequence, the absence of C at position 7 of the antisense sequenceor the absence of G at a position 13 of the sense sequence that is complementary toposition 7 of the antisense sequence, the GC content between about 30% and 52%, and at least 2 A or U bases at position 1 - 5 of the antisense sequence or at least 2 A or U bases at positions 15-19 of the sense sequence that are complementary topositions 1-5 of the antisense sequence.

58. (currently amended) The method according to claim 43, wherein in (c) said method comprises applying the criteria of the absence of C at position 7 of the antisense-sequence or the absence of G at a position 13 of the sense sequence that is complementary to position 7 of the antisense sequence and further comprises

Amendment and Response to Non-Final Office Action

Page 8 of 16

applying the criteria of a GC content of between 30% and 52% and in (d) said candidate siRNA sequence that is selected satisfies both of said criteria of: (i) the absence of \underline{G} at position 7 $\underline{13}$ of the antisense sequence or the absence of \underline{G} at a position of the sense sequence that is complementary to position 7 of the antisense sequence: and (ii) the \underline{GC} content of between 30% and 52%.

- 59. (currently amended) The method according to claim 43, wherein said candidate siRNA sequence that is selected as said siRNA sequence for the target gene satisfies each of the following criteria: the absence of G C at position 4 19 of the antisense sequence and the absence of G G at position 7 13 of the sense antisense sequence.
- 60. (currently amended) The method according to claim 43, wherein in (c), said method comprises applying the criteria of the absence of C at position 7 or the absence of G at a position 13 of the sense sequence that is complementary to position 7 of the antisense sequence and further comprises applying the criteria of a GC content of between 30% and 52%, and wherein said candidate siRNA sequence that is selected as said siRNA sequence for said target gene satisfies all of the criteria of: (i) the absence of C at position 7 of the antisense sequence or the absence of G at a position 13 of the sense sequence that is complementary to position 7 of the antisense sequence; and the GC content of between 30% and 52%.

61-67 (canceled)

- 68. (currently amended) A method for selecting an siRNA sequence for a target gene, wherein said siRNA comprises an antisense sequence that is 19 30 nucleotide bases in length and a sense region sequence that is 19 30 nucleotide bases in length and the sense region comprises a sense sequence that is 19 bases in length and antisense sequence and said sense sequence form a duplex region of 19 30 base pairs, said method comprising the steps:
 - a. (a) selecting a target gene;

Amendment and Response to Non-Final Office Action

Page 9 of 16

 (b) identifying a set of candidate siRNA sequences, wherein each candidate siRNA comprises a sense sequence the antisense sequence of each of saidcandidate siRNA-sequences is at least 79% complementary to a region of the target gene;

e. (c) accessing a computer and causing said computer to apply to each of said candidate siRNA sequences, a computer algorithm, wherein said computer algorithm is stored in computer readable form and comprises a set of one or more criteria selected from the group consisting of a presence of U at position 1 of the antisense sequence or the a presence of A at a position 19 of the sense sequence that is complementary to position 1 of the antisense sequence. a presence of U at position 17 of the antisense sequence or the a presence of A at a position 3 of the sense sequence that is complementary to position 17of the antisense sequence, a presence of A at position 10 of the antisensesequence or the a presence of U at a position 10 of the sense sequence that iscomplementary to position 10 of the antisense sequence, a presence of U atposition 6 of the antisense sequence or the a presence of A at a position 14 of the sense sequence that is complementary to position 6 of the antisensesequence, an absence of G at position 1 of the antisense sequence or the an absence of C at a position 19 of the sense sequence that is complementary toposition 1 of the antisense sequence, an absence of C at position 7 of the antisense sequence or the an absence presence of G at a position 13 of the sense sequence that is complementary to position 7 of the antisense sequence, an absence of A at position 15 of the antisense sequence or the an absence of U at a position 5 of the sense sequence that is complementary to position 15of the antisense sequence and an absence of U at position 9 of the antisense sequence or and the absence of A at a position 11 of the sense sequence thatis complementary to position 9 of the antisense sequence, wherein said sense sequence occupies positions 1-19 of the sense region and wherein when said candidate siRNA sequence is 20-30 bases in length, bases that are within the sense region that are not within said sense sequence occupy positions 1 to 11 of the sense region and positions "1 to "11 of the sense region are immediately

Amendment and Response to Non-Final Office Action

Page 10 of 16

5' of the 5' end of the sense sequence said positions are defined in reference to the 5' end of the antisense sequence within the duplex region;

- d: (d) after step (c) selecting a candidate siRNA sequence from the set of candidate siRNA sequences of step (b) as said siRNA sequence for the target gene, wherein said candidate siRNA sequence satisfies said set of one or more criteria, and wherein said selecting is performed by said computer; and
- e. (e) after step (d) generating an output comprising said siRNA sequence for the target gene, wherein said generating is performed by said computer and said output is displayed in a form that is readable by a human.

69. (canceled)

- 70. (currently amended) The method according to claim 68, wherein the set of one or more criteria includes the presence of U at position 1 of the antisense sequence or the presence of A at a position 10 of the sense sequence that is complementary to position 1 of the antisense sequence.
- 71. (currently amended) The method according to claim 68, wherein the set of one or more criteria includes the presence of U at position 17 of the antisense sequence or the presence of A at a position 3 of the sense sequence that is complementary to position 17 of the antisense sequence.
- 72. (currently amended) The method according to claim 68, wherein the set of one or more criteria includes the presence of A at position 10 of the antisense sequence or the presence of U at a position 10 of the sense sequence that is complementary to position 10 of the antisense sequence.
- 73. (currently amended) The method according to claim 68, wherein the set of one or more criteria includes the presence of U at position 6 of the antisense sequence or the presence of A at a position 14 of the sense sequence that is complementary toposition 6 of the antisense sequence.

Applicants: KHVOROVA et al. Serial No.: 10/714.333

Filing Date: November 14, 2003

Amendment and Response to Non-Final Office Action

Page 11 of 16

74. (currently amended) The method according to claim 68, wherein the set of one or more criteria includes the absence of G at position 1 of the antisense sequence or the absence of C at a position 19 of the sense sequence that is complementary to position.

1 of the antisense sequence.

75. (currently amended) The method according to claim 68, wherein the set of one or more criteria includes the absence of C at position 7 of the antisense sequence or the

absence of G at a position 13 of the sense sequence that is complementary to position

7 of the antisense sequence.

76. (currently amended) The method according to claim 68, wherein the set of one or

more criteria includes the absence of A at position 15 of the antisense sequence or the

absence of U at a position $\underline{5}$ of the sense sequence that is complementary to position

15 of the antisense sequence.

77. (currently amended) The method according to claim 68, wherein the set of one or

more criteria includes the absence of U at position 9 of the antisense sequence or the absence of A at a position 11 of the sense sequence that is complementary to position

9 of the antisense sequence.

78. (canceled)

79. (currently amended) The method according to claim 43, wherein in (b) said <u>sense</u>

antisense sequence is 100% complementary to said the same as a region of said target

gene.

80. (canceled)

Amendment and Response to Non-Final Office Action

Page 12 of 16

81. (currently amended) The method according to claim 68, wherein in (b) said <u>sense</u> antisense sequence is 100%-complementary to said the same as a region of said target gene.

82. (canceled)

83. (canceled)

- 84. (previously presented) The method according to claim 43, wherein said synthesizing comprises chemical synthesis.
- (previously presented) The method according to claim 43, wherein said synthesizing comprises enzymatic synthesis.
- 86. (currently amended) A method for obtaining an siRNA molecule for a target gene, wherein said siRNA molecule comprises an antisense sequence that is 19 30 mueleotide bases in length and a sense sequence that is 19 30 nucleotide bases in length and the sense region comprises a sense sequence that is 19 bases in length and said antisense sequence and said sense sequence form a duplex region of 19 30 base pairs, said method comprising the steps:
 - a. selecting a target gene;
 - b. identifying a set of candidate siRNA sequences, wherein <u>each candidate</u> <u>siRNA comprises a sense sequence</u> the antisense sequence of each of said-candidate siRNA sequences is at least <u>79%</u> complementary to a region of the target gene;
 - e: (c) applying to each of said candidate siRNA sequences a computer algorithm, wherein said computer algorithm comprises a set of four or more criteria selected from the group consisting of: the presence of U at position 1 of the antisense sequence or the a presence of A at a position 10 of the sense sequence that is complementary to position 1 of the antisense sequence, the

Amendment and Response to Non-Final Office Action

Page 13 of 16

presence of U at position 17 of the antisense sequence or the a presence of A at a position 3 of the sense sequence that is complementary to position 17 of the antisense sequence, the presence of A at position 10 of the antisensesequence or the a presence of U at a position 10 of the sense sequence that iscomplementary to position 10 of the antisense sequence, the presence of U atposition 6 of the antisense sequence or the a presence of A at a position 14 of the sense sequence that is complementary to position 6 of the antisensesequence, the absence of G at position 1 of the antisense sequence or the an absence of C at a position 19 of the sense sequence that is complementary toposition 1 of the antisense sequence, the absence of C at position 7 of the antisense sequence or the an absence of G at a position 13 of the sense sequence that is complementary to position 7 of the antisense sequence, the absence of A at position 15 of the antisense sequence or the an absence of U at a position 5 of the sense sequence that is complementary to position 15 of the antisense sequence, the absence of U at position 9 of the antisensesequence or the an absence of A at a position 11 of the sense sequence that iseomplementary to position 9 of the antisense sequence, a GC content between about 30% and 52%, and at least 2 A or U bases at positions 1-5 of the antisense sequence or at least 2 A or U bases at positions 15-19 of the sense sequence that are complementary to positions 1-5 of the antisense sequence. wherein said positions are defined in reference to the 5' end of the antisensesequence within said duplex region wherein said sequence occupies positions 1-19 of the sense region and wherein when said candidate siRNA sequence is 20-30 bases in length, bases that are within the sense region that are not within said sense sequence occupy positions 1 to 11 of the sense region and positions 1 to 11 of the sense region are immediately 5' of the 5' end of the sense sequence;

d. (d) after step (c) selecting a candidate siRNA sequence from the set of candidate siRNA sequences of step (b) as an siRNA sequence for the target gene, wherein said candidate siRNA sequence satisfies said set of four or more criteria; and

Amendment and Response to Non-Final Office Action

Page 14 of 16

- e. (e) after step (d) synthesizing said siRNA molecule for said target gene, wherein said siRNA molecule for said target gene comprises said siRNA sequence for the target gene, whereby said siRNA molecule for said target eene is obtained.
- 87. (currently amended) The method according to claim 86, wherein in (c) said method comprises applying a set of five or more criteria selected from the group consisting of: the presence of U at position 1 of the antisense sequence or the presence of A at a position 19 of the sense sequence that is complementary to position 1 of the antisensesequence, the presence of U at position 17 of the antisense sequence or the presence of A at a position 3 of the sense sequence that is complementary to position 17 of the antisense sequence, the presence of A at position 10 of the antisense sequence or the presence of U at a position 10 of the sense sequence that is complementary toposition 10 of the antisense sequence, the presence of U at position 6 of the antisensesequence or the presence of A at a position 14 of the sense sequence that is complementary to position 6 of the antisense sequence, the absence of G at position 1of the antisense sequence or the absence of C at a position 19 of the sense sequence that is complementary to position 1 of the antisense sequence, the absence of C atposition 7 of the antisense sequence or the absence of G at a position 13 of the sense sequence that is complementary to position 7 of the antisense sequence, the absenceof A at position 15 of the antisense sequence or the absence of U at a position 5 of the sense sequence that is complementary to position 15 of the antisense sequence, the absence of U at position 9 of the antisense sequence or the absence of U at a position 11 of the sense sequence that is complementary to position 9 of the antisensesequence, a GC content between about 30% and 52%, and at least 2 A or U bases atpositions 1-5 of the antisense sequence or at least 2 A or U bases at positions 15-19 of the sense sequence that are complementary to positions 1.5 of the antisensesequence, and wherein in (d) said candidate siRNA sequence that is selected as said siRNA sequence for said target gene satisfies said set of five or more criteria.